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ABSTRACT
Purpose: To evaluate the rate and onset of intraoperative and postoperative complications post-phacoemulsi-
fication. Methods: One hundred sixty-two eyes of 145 patients with uveitis who underwent phacoemulsification
between 2006 and 2009 were identified through surgical record review. Fifty-nine eyes of 46 patients met
the inclusion criteria. Hazard ratio (HR) and Kaplan-Meier survival probability were calculated for each class
of uveitis. Results: Macular edema (ME) resulted to be associated to chronic postoperative inflammation
(r= 0.6; p= 0.00) and mostly related to patients who presented more than one postoperative relapse/year (r= 0.2;
p= 0.02). Fuchs uveitis resulted to be a risk factor for posterior capsule opacification (PCO) (HR 3.36
IC95%1.0-10.5; p= 0.03). Hypotony and elevated intraocular pressure (IOP) were detected in the anterior uveitis
group (0.02 EY). Conclusion: The HR to develop ME was significantly related to chronic anterior uveitis. PCO
and elevated IOP are most frequent in Fuchs uveitis. The postoperative visual acuity result was good among all
the uveitis groups.
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INTRODUCTION
Cataract is one of the most common complications in
many forms of uveitis with an incidence of up to
50%.1 Several studies have only reported the compli-
cations regarding cataract and uveitis,2,3 but it would
be interesting to highlight the relationship among the
types of uveitis and cataract outcomes. The uveitic
cataract offers special challenges for the surgeon, such
as a miotic pupil, iris atrophy, pupillary membrane
formation, band keratopathy, and bleeding from
abnormal fragile iris vessels. Surgery triggers a local
production of inflammatory mediators, which can
lead to a flare-up of a quiescent uveitis. Posterior
chamber intraocular lens (IOL) implantation is suc-
cessful regarding the vision of these patients.4
A recent review based on several trials showed that
there is an uncertainty as to which type of IOL
provides the best visual and clinical outcomes in
people with uveitis undergoing cataract surgery.5
However, evidence of a superior effect of hydrophobic
acrylic lenses over silicone lenses was already
described in the literature.6 Furthermore, PCO
remains to be the single most common cause of
reduced visual acuity after cataract surgery in uveitic
patients because of their underlying pathology and
possibly their younger age at the time of cataract
surgery.7 Visual and clinical outcomes may also vary
with different surgical techniques for cataract extrac-
tion and IOL implantation.8,9 The aims of the study
were to value ocular intraoperative complications,
detect the onset of ocular postoperative complications,
and assess the postoperative best-corrected visual
acuity (BCVA) in uveitis patients after phacoemulsi-
fication with IOL implantation among the different
types of uveitis.
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MATERIALS AND METHODS
Patients with a diagnosis of uveitis who underwent
phacoemulsification at the Ocular Immunovirology
Service of Sapienza University of Rome between 2006
and 2009 were identified through surgical records
(n= 145; 162 eyes). From these, 59 eyes of 46 patients
met the inclusion criteria. The University of Rome
‘‘Sapienza’’ Ethical Board Committee approved the
retrospective revision and analysis, for scientific
purposes, of the ophthalmological data obtained
from the patients included in the present investiga-
tion. Informed consent was obtained from all patients
involved in this research. The study was conducted in
accordance with local and regional regulations, good
clinical practices, and the tenets of the Declaration of
Helsinki.
Inclusion criteria were diagnosis of uveitis, aged 18
or older at the time of cataract extraction. Exclusion
criteria were ocular conditions such as an abnormal
cornea including cornea guttata, endothelial dystro-
phy, corneal edema, glaucoma, macular degeneration,
previous intraocular surgery, history of penetrating
trauma, and endophthalmitis. Patients with a history
of preoperative ME and non-implanted eyes were
excluded as well as patients with diabetes mellitus.
We only included patients where phacoemulsification
with IOL implantation was performed by the same
surgeon. The ophthalmological examination included
BCVA using Snellen charts where each decimal
notation was converted to logMar value, intraocular
pressure (IOP) assessment using Goldmann applana-
tion tonometer, slit-lamp biomicroscopy, and fundus
examination using bilateral indirect ophthalmoscope.
Cataract was defined using the classification LOCS
III.10 IOL calculation was provided using IOL Master
(Carl Zeiss Meditec, Inc., Dublin, California) or
A-Scan (Cinescan S Ophthalmic Ultrasound System,
Quantel Medical, France) when the instrument was
not able to calculate IOL power. Preoperative and
postoperative uveitis relapses were evaluated count-
ing the number of the relapses divided, respectively,
for the preoperative and postoperative follow-up
time. Intraoperative complications included the use
of iris hooks, posterior capsule rupture, and anterior
vitrectomy. Postoperative complications included ME,
PCO, hypotony, and elevated IOP. ME was defined as
the presence of macular thickening with or without
cyst formation seen by clinical examination and/or
spectral domain OCT.11 PCO was evaluated following
the dilation of the pupil using slit-lamp retroillumina-
tion.12 PCO was only considered as a complication
when significant opacity involved a large fraction of
capsule area behind the IOL optic, causing visual
acuity reduction.
Ocular hypertension was defined as IOP elevation
421 mmHg and hypotony was defined as an IOP
55 mmHg. Severe postoperative inflammation was
defined as the persistence of anterior chamber inflam-
mation more than 3+ cells for a period longer than
three months.
Preoperative treatment
Three days before surgery, steroid therapy was
introduced or increased to 1/2 mg/kg/day in patients
presenting an autoimmune uveitis. For herpetic uve-
itis, valaciclovir therapy was introduced on the day of
surgery at 3 per 1 g/day for herpes zoster uveitis, and
at 3 per 500 mg/day for herpes simplex uveitis. No
additional therapy was given to Fuchs heterochromic
cyclitis. Steroid therapy was progressively tapered or
increased after surgery according to the postoperative
inflammation. Topical steroids (0.1% dexamethasone
phosphate) were applied six times per day during the
first postoperative day and then progressively
reduced according to the level of ocular inflammation.
Surgery
Preoperatively, tropicamide 1% and phenylephrine
10% were instilled every 30 minutes two hours before
surgery. Surgery was performed using periocular
anesthesia. A standard phacoemulsification technique
with a corneal or limbal approach was used. Sodium
hyaluronate 3.0%–chondroitin sulfate 4.0% (Viscoat)
or sodium hyaluronate 1.4% (Healon GV) was used
for synechiolysis and for creating the capsulorhexis. In
some cases, iris hooks were used to dilate the pupil.
Phacoemulsification was done using the divide and
conquer technique. After cortical clean-up, the pos-
terior surface of the anterior capsule was aspirated.
The IOL was implanted in the capsular bag and in the
case of posterior capsule rupture in the sulcus. Some
incisions were sutured with 10-0 nylon in a configur-
ation of the surgeon’s choice. A subconjunctival
injection of 4 mg betamethasone was given at the
end of surgery.
Statistical analyses
Patient data were entered in a computer-based
standardized data entry form for statistical analysis.
Incidence rates were calculated as the number of
events divided by the number of eyes at risk.
Kolmogorov-Smirnov test was applied for all data
samples in order to check normality. Bivariate correl-
ations were evaluated using Pearson or Spearman
correlation coefficients, depending on whether nor-
mality could be assumed or not. When parametric
statistical analysis was possible, Student t test for
paired data was applied to assess the significance of
differences between preoperative and postoperative
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data, whereas the Wilcoxon Rank Sum test was
applied when it was not possible. For the comparison
of several related samples, the Friedman test was
used. The long rank test was used to compare Kaplan-
Meier curves among the complications of the different
uveitis types. For the risk factor analyses, HR using
COX regress analysis was calculated. A p value50.05
was considered significant. All of the analyses were
performed using SPSS 21.0 statistical software (LEAD
Technologies).
RESULTS
Characteristics of the study population are summar-
ized in Table 1 and cataract distribution is reported in
Table 2. Fuchs uveitis showed a statistically significant
association with subcapsular form (r= 0.2; p= 0.02)
and chronic anterior uveitis with nuclear form (r= 0.3;
p= 0.02).
Hydrophobic acrylic IOLs were implanted.
Acrysof Alcon was implanted in 39 eyes (66.1%),
Tecnis ZCB00 Abbot in 14 eyes (23.7%), and
VA60BB Hoya in six eyes (10.1%).
The intraoperative complications included one case
(1.7%) of posterior capsule rupture with anterior
vitrectomy and, in 18 eyes (30.5%), iris hooks were
used to dilate the pupil. The use of iris hooks was
significantly associated with the chronic anterior
uveitis group (r= 0.4; p= 0.01) and in the nuclear
cataract group (r= 0.3; p= 0.01). The subcapsular
cataract group showed a negative association with
the use of iris hooks (r=0.3; p= 0.01).
Among the long-term complications, the incidence
of ME was 0.02 EY. Six cases (10.2%) of ME were
detected. Four cases in the anterior uveitis (6.8%) and
two cases in the panuveitis (3.4%) group. The median
time of onset after cataract surgery was 51.19 ± 16.9
months (95 IC% 50.39–51.80). In the anterior group, it
was 52.36 ± 16.93 months (95 IC% 34.59–73.7) and, in
the panuveitis group, it was 57.6 ± 23.15 months (95
IC% 0.31–265.59). The differences among the groups
were not statistically significant (p= 0.30). No group of
uveitis showed to be a specific risk for developing
ME. It turned out to be highly associated with chronic
postoperative inflammation (r= 0.6; p= 0.00) and most
associated in patients who presented more than one
postoperative relapse/year (r= 0.2; p= 0.02)
The incidence of PCO was 0.07 EY. Sixteen cases of
PCO (27.1%) were identified. Eleven cases (18.6%) in
the anterior uveitis group, two (3.4%) cases in the
TABLE 1. Characteristics of the study population.
Patient-specific characteristics Value
Number of patients 46
Male (%) 22 (47.8)
Female (%) 24 (52.2)
Number of eyes 59
Median follow up months ± SD (range) 42.10 ± 55.80 (9–396)
Median age at the time of uveitis diagnosis years ± SD (range) 43.35 ± 19.81 (4–78)
Median duration of uveitis inactivity before surgery months ± SD (range) 21.14 ± 11.56 (3–502).
Median age at the time of the cataract surgery years ± SD (range) 61.44 ± 18.16 (22.9–81.15)
Uveitis distributions
Anterior Associated to HLA- B27 1 (1.7)
Number of eyes (%) 33 (55.9) Fuchs 7 (11.9)
Herpetic uveitis 13 (22)
Ulcerative colitis 4 (6.8)
Tubercolosis 2 (3.4)
Idiopathic 6 (10.2)
Intermediate
Number of eyes (%) 3 (5)
Posterior Toxoplasma retinitis 2 (3.4)
Number of eyes (%) 10 (16.9) Tubercolosis 3 (5.1)
Vokt Koyanagi Harada disease 2 (3.4)
Serpiginous choroiditis 1 (1.7)
Multifocal choroiditis 2 (3.4)
Panuveitis Behc¸et 6 (10.2)
Number of eyes (%) 13 (22) Tubercolosis 1 (1.7)
Idiopathic 6 (10.2)
TABLE 2. Cataract distribution and IOL implanted.
Cataract distribution Number of eyes (%)
Nuclear 31 (52.4)
Cortical 9 (15.2)
Nuclear + subcapsular 1 (1.69)
Cortical + subcapsular 1 (1.69)
Nuclear + cortical + subcapsular 7 (11.8)
Subcapsular 10 (16.9)
Uveitis and cataract phacoemulsification complications 3
! 2015 Informa Healthcare USA, Inc.
Se
m
in
 O
ph
th
al
m
ol
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
2.
23
6.
18
9.
10
1 
on
 0
2/
20
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
posterior and panuveitis groups, respectively, and
one (1.7%) case in the intermediate group. The median
time of onset after surgery was different among
the types of uveitis. For anterior uveitis, a median
onset was 12.32 ± 17.59 months (95% IC 0.41–24.04),
in posterior and panuveitis it was 25.34 ± 10.13
(95% IC 0.22–116.4) and 22.29 ± 12.21 (95% IC 0.17–
131.90), respectively. The differences among the
groups were not statistically significant (p= 0.42).
Fuchs uveitis was a risk factor for PCO (HR 5.5;
95%IC 0.9–30.39; p= 0.05) as well as anterior chronic
uveitis. However, the value did not reach statistical
significance (HR 3.6; 95% IC 0.69–19.61; p= 0.1).
Kaplan-Meier analyses among the Fuchs and PCO is
shown in Figure 1.
The incidence of PCO did not show statistically
significant differences among the different groups of
lenses implanted (p= 0.65). PCO was not related to
chronic postoperative inflammation (r= 0.03; p= 0.82).
Hypotony was detected only among the anterior
uveitis group. Three cases were detected (5.1%). The
incidence of hypotony was 0.02 EY. The median time
of onset was 13.2 ± 12.74 months (95% IC 0.31–43.34).
Among the anterior uveitis group, only chronic
uveitis showed a low risk related to hypotony (HR
0.4; 95% IC 0.03–4.63; p= 0.04). Hypotony proved to be
more associated with postoperative chronic inflam-
mation (r= 0.35; p= 0.02).
Elevated IOP was also more common in anterior
uveitis. Six cases were reported (10.2%), five cases in
the anterior uveitis group (8.5%) and one case in the
panuveitis group (1.7%). No comparative statistical
analysis among the different classes of uveitis was
performed in this case. The incidence was 0.04 EY. The
median time of onset was 2.77 ± 3.27 months (95% IC
0.17–6.20). Fuchs uveitis seems to be a risk for
elevated IOP, but the value was not statistically
significant (HR 2.79; 95% IC 0.39–19.97; p= 0.30).
Elevated IOP was not associated with severe post-
operative inflammation (r= 0.1; p= 0.10).
Table 3 summarizes the distributions of complica-
tions among the different groups of uveitis.
The Kaplan-Meier curve was applied to analyze
the occurrence of complications among the different
classes of uveitis (Figure 2A–D).
Severe postoperative inflammation was found in
three eyes (5.1%). Two of them were affected by
panuveitis (3.4%) and one by anterior uveitis (1.7%).
The mean preoperative relapse of uveitis per year
was 0.4 ± 0.08 (range: 0–3.3) and the mean post-
operative relapse per year was 0.2 ± 0.05 (range:
0–2.09). No statistically significant difference was
FIGURE 1. Kaplan-Meier curve of PCO follow-up after cataract surgery among the patients with diagnosis of Fuchs uveitis and
other uveitis.
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found between the preoperative and postoperative
relapse (p= 0.09). Five eyes had more than one
postoperative relapse/year. The risk of developing
postoperative complications in these groups is
reported in Table 4.
The mean preoperative BCVA at the preoperative
visit was 0.49 ± 0.42 logMar and, at the end of the
follow-up, 0.20 ± 0.31 logMar. The difference between
the visual acuity was significant (p= 0.00) Fuchs
uveitis was significantly associated with the best
FIGURE 2. Kaplan-Meier curve of (A) ME, (B) PCO, (C) elevated IOP, (D) hypotony among patients of different uveitis groups after
cataract surgery.
TABLE 3. Hazard risk of complications among different classes of uveitis.
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p value HR (95% CI) p Value
Complications Macular edema Posterior capsule opacification Elevated IOP Hypotony
Anterior 1.73 (0.3–9.7) 0.52 2.88 (0.2–13.1) 0.17 4.4 (0.5–37.8) 0.17 55.10 (0.05–63.1) 0.40
Fuchs 0.40 (0–16.5) 0.55 3.36 (1.0–10.5) 0.03* 5.72 (1.0–31.4) 0.04* 0.42 (0–54.4) 0.70
Herpetic uveitis 0.21 (0–95.7) 0.36 0.22 (0.48–1.1) 0.06 0.89 (0.1–5.3) 0.91 3.4 (0.3–38) 0.31
Chronic uveitis 29.2 (0.01–84.4) 0.02* 1.6 (0.49–5.57) 0.41 0.34 (0.38–3.08) 0.34 0.63 (0.57–6.99) 0.70
Intermediate 0.46 (0–75.7) 0.71 3.56 (0.32–39.5) 0.30 0.46 (0–28.0) 0.69 0.04 (0–15.1) 0.83
Posterior 0.03 (0–73.3) 0.38 1.36 (0.19–9.69) 0.75 0.03 (0–28.4) 0.46 0.03 (0–11.6) 0.61
Panuveitis 1.09 (0.19–6.03) 0.91 0.39 (0.09–1.72) 0.22 0.65 (0–5.64) 0.70 0.03 (0–25.8) 0.51
Behcet 0.40 (0–15.1) 0.55 1.17 (0.26–5.18) 0.83 0.42 (0–32.3) 0.58 0.42 (0–30.8) 0.69
*Statistical significant value.
Uveitis and cataract phacoemulsification complications 5
! 2015 Informa Healthcare USA, Inc.
Se
m
in
 O
ph
th
al
m
ol
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
2.
23
6.
18
9.
10
1 
on
 0
2/
20
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
visual outcome (r= 0.2; p= 0.04). Final BCVA did not
show a statistically significant difference among the
different groups of lenses implanted (p= 0.64). The
preoperative and postoperative visual acuity reported
for the different groups of uveitis are shown in
Figure 3. Risk factors of developing a BCVA lower
than 0.3 logMar during the follow-up are reported in
Table 5.
DISCUSSION
The postoperative and long-term complications for
eyes with uveitis and cataract treated by phacoemul-
sification and IOL implantation have been reported in
several articles,13,14 without an evaluation of the
postoperative and long-term risk associated with the
different types of uveitis diagnosis.
Chronic anterior uveitis showed a statistically
significant association with cataract nuclear form
(r= 0.38; p= 0.02) and Fuchs uveitis with the
subcapsular form (r= 0.2; p= 0.02). This data can be
correlated to those found in the literature.15
Intraoperative Complications
The intraoperative use of iris hooks to dilate the
pupils has proved to be a useful technique during
cataract surgery.16 Synechiolysis and removal of
pupillary membrane were performed. Then, the
iris hooks were placed and removed through mul-
tiple corneal paracentesis. In 18 eyes (30.5%), iris
retractors were used. The use of iris hooks was
significantly associated with the group of chronic
anterior uveitis (r= 0.4; p= 0.01) and their use was
more related to postoperative severe inflammation
(p50.05). Final BCVA lower than 0.3 logMar was
not significantly associated with the use of iris
hooks. (p= 0.20).
The intraoperative complications included one
case (1.7%) of posterior capsule rupture which
FIGURE 3. Graph A reports the preoperative visual acuity differences among classes of uveitis. In anterior uveitis, it was 0.4 3 ± 0.28
logMar (0–1); in the intermediate uveitis, 0.1 ± 0.17 logMar (0–0.3); in the posterior uveitis, it was 0.6 ± 0.58 logMar (0–1.69); in the
panuveitis, it was 0.50 ± 0.44 logMar (0–1.69). Graph B reports the visual acuity at the last follow-up examination. In the anterior
uveitis group, the visual acuity was 0.17 ± 0.33 logMar (0–1); in the intermediate uveitis, 0.01 ± 0.02 logMar (0–0.4); in the posterior
uveitis, it was 0.23 ± 0.32 logMar (0–1); in the panuveitis, it was 0.30 ± 0.35 logMar (0–1). The differences among the groups of uveitis
were not statistically significant. Preoperative visual acuity (p= 0.22) and postoperative visual acuity (p= 0.25) (Kruskal Wallis)
are shown.
TABLE 5. Risk factors for vision loss during follow-up.
Complications HR (95% CI) p Value
Posterior capsule rupture 3.0 (0.80–11.4) 0.28
Use of iris hook 5.0 (0.25–99.9) 0.10
Macular edema 1.0 (0.11–9.91) 0.96
Elevated IOP 0.7 (0.9–6.9) 0.83
Hypotony 0.1 (0–7.3) 0.99
Postoperative severe inflammation 2.3 (0.5–11.3) 0.06
More than 1 relapse year 3.3 (0.5–20.3) 0.13
TABLE 4. Risk factor for developing postoperative
complications among patients with more than one
postoperative relapse year.
Complications HR (95% CI) p Value
Macular edema 7.7 (1–55.9) 0.04*
Posterior capsule opacification 1.8 (0.3–10.8) 0.5
Elevated IOP 5.3 (0.8–32.0) 0.06
Hypotony 7.2 (0.6–8.3) 0.1
*Statistical significant value.
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required anterior vitrectomy. Other authors reported
posterior capsule rupture, with vitreous loss the
most common intraoperative complication in this
group of patients. According to these results, it
was seen in 3% of patients who underwent
phacoemulsification.17
Postoperative Complications
Macular edema
In this study, ME post cataract surgery was detected
in 8.47% of eyes. No group of uveitis showed to be at a
statistically significant risk for developing ME. The
incidence of postoperative ME in uveitic eyes was
10% in previous studies.13 Agrawal et al. reported an
increased risk of developing ME postoperatively in
eyes with previous episodes of ME.16
The incidence of ME following phacoemulsification
has been reported to range from 12% to 59% in eyes
with pars planitis.18 In our study, the sample of
intermediate uveitis was too small to relate with other
data. We observed six cases of ME after cataract
surgery. This value could appear to be low, but it is
important to remember that eyes with previous
episodes of ME and patients with diabetes were
excluded from the study.
ME following cataract surgery or Irvine-Gass syn-
drome is induced by inflammatory mediators and
consists of intraretinal perifoveal fluid accumulating
in the outer plexiform and inner nuclear layers,
forming cystic spaces and decreases in retinal func-
tion.19 Irvine-Gass syndrome normally occurs four to
six weeks postoperatively, but can even occur in the
first week after surgery.20 Its incidence following
modern cataract surgery is 0.1%–2.35%.21 The median
time of ME onset observed after cataract surgery in
our group of uveitic patients was 51.19 ± 16.9 months
(95% IC 50.39–51.80).
These patients developed ME with a late onset
compared to Irvine-Gass syndrome. The different
pathogenesis theory in these two different presenta-
tions of postsurgery ME should probably be con-
sidered. It is possible that different factors increase
inflammation or capillary permeability in uveitic and
nonuveitic eyes. The eye with the posterior capsule
rupture presented postoperative ME 21 months after
cataract surgery. Posterior capsule rupture is a known
risk factor for developing ME.19 Furthermore, in our
study, ME proved to be highly associated with chronic
postoperative inflammation (p= 0.00), mostly occur-
ring in patients who presented more than one post-
operative relapse/year (r= 0.2; p= 0.02). The risk of
developing it among these patients is highly statistic-
ally significant (HR 7.7; IC 95% 1–55.9; p= 0.04).
Another study demonstrated that the development
of severe uveitis in the first week postsurgery was
associated with a greater incidence of ME.22
We can speculate that iris retractors prove to be
associated with postoperative severe inflammation.
Some authors reported that iris manipulation at the
time of surgery was not related to an increased risk
of postoperative ME, but iris incarceration and the
use of iris-fixated lenses are associated with increased
risk.19 Also, Nd-YAG capsulotomy is considered to be
a risk for ME. Among our patients who underwent
Nd-YAG capsulotomy (25.42%), only one (6.66%)
developed ME. Capsulotomy was performed in this
patient 47 months after cataract extraction.
In our study, 80% of patients who presented
postoperative ME had cystoids macular edema
(CME), and only 20% had diffuse macular edema,
according to the ME classification in uveitis with
SD-OCT proposed recently in the literature.23
Munk et al. described the progression and reso-
lution of uveitis-associated CME using SD-OCT and
found predictive factors for successful intravitreal
triamcinolone acetonide therapy. In their study, none
of the eyes developed serous subretinal detachment
(SRD) of the neuroepithelium detachment during ME
relapse.24 In our study, 50% of eyes with ME had a
relapse, and 20% of these eyes had an ME relapse
associated with SRD. In the Munk study, the main
effect variables SRD and absence of epiretinal mem-
brane (ERM) were associated with greater BCVA
improvement.24 In our series, only one eye presented
SRD during an ME relapse with an excellent visual
recovery following therapy, and two eyes affected by
ERM did not present relapse. Five eyes were treated
by a series of posterior sub-Tenon injections of
repository corticosteroids. The number of injections
ranged from two to five, depending on the response to
the therapy evaluated with BCVA and SD-OCT. One
eye was treated with a systemic steroid, tapering the
steroid dosage each week.
Roesel et al. demonstrated that a single intraopera-
tive orbital floor injection of triamcinolone acetonide is
as effective on postoperative inflammation, ME, and
visual outcome as a four-week course of postoperative
oral prednisolone in cataract surgery with IOL implant-
ation in uveitic patients.25 In our study, all treated eyes
had a good response to therapy with regression or
significant reduction of central foveal thickness,
demonstrating that posterior sub-Tenon injections of
repository corticosteroids is an effective therapeutic
alternative in the treatment of postoperative ME.
Posterior capsule opacification
Most previous publications found that uveitic eyes
with placement of an IOL in the bag had a higher
risk for PCO compared to non-uveitic eyes. The
incidence in non-uveitic eyes with an acrylic IOL
is closer to 10-15%.26 In eyes having standard
phacoemulsification. the hydrophobic acrylic IOL
had a median capsulotomy-free survival 4150
months,27 considerably higher than median PCO
Uveitis and cataract phacoemulsification complications 7
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onset in uveitic eyes in our study. Even if post-
operative inflammation is commonly considered to be
a risk factor for PCO, in our study PCO was not
associated with chronic postoperative inflammation
(p= 0.82). Suresh et al. reported that PCO occurred in
42% of eyes in patients who had undergone phacoe-
mulsification with IOL implantation with five years of
follow-up and Nd-YAG capsulotomy was required in
21% of uveitis.28 In our study, the rate of postoperative
PCO resulted in 27.12% (16 eyes) and Nd-YAG
capsulotomy was performed in 15 eyes (25.42%).
Usually, 1.5 to 2mJ per pulse from Q-switched Nd-
YAG laser was sufficient to open the posterior
capsule. After the laser procedure, one drop of timolol
maleate 0.5% eye drops and brimonidine tartrate 0.2%
was applied. We used oral carbonic anhydrase inhibi-
tors, acetazolamide 250 mg, at the end of the proced-
ure and repeated it after four hours. Dexamethasone
0.1% was supplied as one drop four times daily and
then tapered depending on the degree of cellular
reaction. In one eye the Nd-YAG laser was not
performed because the patient chose to postpone the
procedure. The median age at the time of surgery of
our patients was 47 years (range: 19–89 years).
Compared to Suresh data, the lower incidence of
PCO of our sample is probably due to the higher
median age at the time of surgery. Fuchs hetero-
chromic iridocyclitis proved to be a risk factor for
PCO (HR 5.5; IC 95% 0.9–30.39; p= 0.05). Javadi et al.
reported that PCO was a common complication in
Fuchs uveitis and developed in the follow-up period
of 17.8 ± 8.7 months.29 Anterior chronic uveitis group
did not demonstrate statistical significance related to
PCO (HR 3.6; IC 95% 0.69–19.61; p= 0.1), even though
anterior chronic uveitis represented 18.6% cases of
postoperative PCO. In other studies, between 12.7%
and 28.7% of the cases with PCO were observed in
the anterior uveitis group.13,14 In anterior uveitis,
a PCO median onset was 12.32 ± 17.59 months (95%
IC 0.41–24.04); in posterior and panuveitis, it was
25.34 ± 10.13 (95% IC 0.22–116.4) and 22.29 ± 12.21
(95%IC 0.17–131.90), respectively. The differences
among the groups were not statistically significant
(p= 0.42). However, PCO was manifested earlier in
the anterior uveitis group compared to the others.
A possible bias could be that the anterior uveitis
group was of a younger age at the time of surgery
compared to the others, and this data could be a bias
in this evaluation. A statistically significant difference
between the different groups of hydrophobic acrylic
IOL implanted and incidence of PCO were not
revealed (p= 0.65).
Elevated IOP
Another potential postoperative complication is ele-
vated IOP. 10.1% of eyes after surgery developed
elevated IOP. The elevated IOP was controlled by the
application of eye drops in four eyes. Timolol maleate
0.5% one drop two times a day was enough in one
eye (1.7%), and timolol maleate 0.5% and dorzolamide
2% one drop two times a day in three eyes (5.1%).
Two eyes (3.4%) underwent filtration surgery treat-
ment because the systemic therapy was not enough
and the visual field worsened.
Fuchs uveitis seemed to be a risk factor for
postoperative elevated IOP, but the value was not
significant (HR 2.79; IC 95% 0.39–19.97; p= 0.3).
Permanent IOP elevation after cataract extraction
was reported to develop in 3% to 35% during the
follow-up period.30 We reported 8.47% of eyes with
elevated IOP among anterior uveitis. Kosker et al.
described a raised IOP in 7.27% of eyes with anterior
uveitis.13 In our series, elevated IOP was not
associated with severe postoperative inflammation
(p= 0.1).
Hypotony
In our series, 5.08% of eyes showed postoperative
hypotony. This complication proved to be more
frequent in patients with postoperative chronic
inflammation (p= 0.02). Hypotony was detected only
among the anterior uveitis group, but with a low risk
association (HR 0.4; 0.03–4.63; p= 0.04). Previous
studies had an incidence of 1.8% of postoperative
hypotony.13 Difficult control of uveitis is a high risk of
severe postoperative inflammation and hypotony.
Therefore, careful ultrasonic biomicroscopy could be
required in eyes with relative preoperatory hypotony
to assess the state of the ciliary body. The risk of
hypotony is high if the ciliary body proved atrophic.16
Posterior synechiae
In our series, there was no evidence of postoperative
posterior synechia. Other studies present very high
rates of posterior synechia (25%).14 In our study, the
low rate could be the result of the use of hydrophobic
acrylic IOL.
Visual acuity outcome
The mean preoperative BCVA at the preoperative visit
was 0.49 ± 0.42 logMar and, at the end of follow-up,
0.2 ± 0.31 logMar. The difference between the visual
acuity was significant (p= 0.00). Postoperative severe
inflammation did not reach a statistical significant
value, even if it seemed to be a risk of BCVA
reduction. Patients with more than one postoperative
relapse year seemed to have a risk of developing
a visual acuity reduction, but the value was not
statistically significant (HR 3.3; IC 95% 0.5–20.3;
p= 0.1).
Javadi et al. reported in Fuchs uveitis a post-
operative visual acuity of 0.3 logMar or better in all
41 eyes that underwent phacoemulsification and lens
implantation.29 No statistical significant difference
between the different groups of hydrophobic acrylic
IOL implanted and final BCVA was found (p= 0.64).
8 A. Abbouda et al.
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Alio´ et al. found that 46.3% of eyes had a best-
corrected visual acuity of 0.3 logMar or better at one
year using a variety of IOL materials and designs.6
Ram et al. reported in their group with a mean age
of 42.3 years ± 13.98 consisting of 108 eyes with a
BCVA improvement postoperatively of 0.3 logMar or
better in 71.30% of the patients. 15.74% had a final
BCVA of 0.48 to 0.80 logMar and 5.55% of 1.00
logMar.14
In our study, 74.57 % of patients had a final BCVA
better than 0.48 logMar. The high rate of significant
postoperative improvement in BCVA was influenced
by the fact that the exclusion criteria considered
diseases that affected preoperative macular
involvement.
One limitation of this study is that the group of
intermediate uveitis was quite small compared to the
other groups. Therefore, no significant comparisons
could be made with this group. However, we did also
include the description of this group to provide an
overview of all uveitis classes.
In summary, this study reports the outcomes and
complications of the cataract surgery for patients with
uveitis. The data related to the preoperative and
postoperative complications suggest that phacoemul-
sification is safe and needed for a good visual
recovery in most uveitic patients with cataract.
Similar results were also reported by a recent
metanalysis.31 The HR to develop ME is significantly
associated with the group of chronic anterior uveitis,
and PCO and elevated IOP are more frequent in Fuchs
uveitis. The postoperative visual acuity had good
results among all the uveitis groups. No statistical
difference was identified among them. The medical
management and parasurgical procedures used in
postoperative complications of phacoemulsification
with IOL implantation help widely in the persistence
of visual recovery due to cataract surgery. Good visual
outcomes and low complication rates can be obtained
when ocular inflammation is under control.
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